GURU.Markets stock price, segment price, and overall market index valuation
The company's share price InflaRx N.V.
InflaRx is a German biotech company developing drugs for the treatment of inflammatory diseases. Its stock price is highly volatile, driven by clinical trial results and regulatory decisions in Europe and the US.
Share prices of companies in the market segment - Pharma immune
InflaRx is a German biotech company developing complement C5a inhibitors for the treatment of severe inflammatory diseases, including hidradenitis suppurativa and COVID-19. We have classified it in the "Pharma immune" segment. The chart below shows the overall dynamics in the immunology sector, where scientists are searching for ways to control inflammatory processes in the body.
Broad Market Index - GURU.Markets
InflaRx is a German biotech company developing antibody-based drugs to control inflammation. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how InflaRx shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IFRX - Daily change in the company's share price InflaRx N.V.
InflaRx N.V.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its inflammatory disease drugs, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Pharma immune
InflaRx N.V.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its inflammatory disease drugs, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
InflaRx is a German biotech company developing drugs to control inflammation. Its shares are driven by news of clinical trials. The dynamics of such international players adds global context to the volatility of the US market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization InflaRx N.V.
InflaRx N.V.'s year-over-year performance is the story of its complement-targeting drug. Its 12-month market cap is crucially dependent on FDA decisions and clinical trial data. Approval of its drug for the treatment of severe COVID-19 and other inflammatory diseases could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma immune
InflaRx N.V. is a German biotech company developing drugs for the treatment of severe inflammatory diseases. Its success depends on the commercialization of its approved drug. The chart shows how its niche strategy and competitive environment influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
InflaRx is a biopharmaceutical company whose stock performance is driven by the success of its product commercialization and research progress. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization InflaRx N.V.
InflaRx is a German biotech company specializing in inflammatory diseases. Its monthly performance is driven by clinical and regulatory events. News about the trial results of its lead drug, vilobimab, and FDA/EMA decisions cause sharp fluctuations in its stock.
Monthly dynamics of market capitalization of the market segment - Pharma immune
InflaRx N.V. is a clinical-stage biopharmaceutical company developing new treatments for severe and life-threatening inflammatory diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its approach, targeting complement inhibition, could help treat conditions such as sepsis.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
InflaRx is a biopharmaceutical company developing drugs for inflammatory diseases. Its shares move not with the market, but on research news. The chart demonstrates extreme volatility and a complete dependence of monthly performance on research successes or failures in trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization InflaRx N.V.
InflaRx, a German biotech company developing drugs for inflammatory diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials and regulatory decisions, each of which could dramatically change the outlook.
Weekly dynamics of market capitalization of the market segment - Pharma immune
InflaRx is a German biotech company focused on treating inflammatory diseases. The chart compares its performance, driven by news from Europe, with the global pharmaceutical sector. This helps understand how the market views its scientific approaches against the backdrop of overall industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
InflaRx is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that IFRX's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
IFRX - Market capitalization of the company InflaRx N.V.
The InflaRx chart is a financial map of the fight against inflammation. This German biotech's market cap reflects the hopes for its drugs, which block a key component of the immune system (C5a). Its volatility mirrors the results of clinical trials for the treatment of rare and severe inflammatory diseases.
IFRX - Share of the company's market capitalization InflaRx N.V. within the market segment - Pharma immune
InflaRx's market share in the immunology sector reflects its leadership in the development of drugs targeting the complement system. Its market share is driven by the success of its drugs in treating severe inflammatory diseases, making it a key player in this cutting-edge field of medicine.
Market capitalization of the market segment - Pharma immune
InflaRx is a German biotech company focused on treating severe inflammatory diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect investors' high hopes for the development of new, more effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
InflaRx is a German biopharmaceutical company developing drugs to control inflammatory processes, particularly the complement system. Its market capitalization reflects its scientific expertise. The chart below shows the weight of companies working in this complex field of immunology.
Book value capitalization of the company, segment and market as a whole
IFRX - Book value capitalization of the company InflaRx N.V.
The book value of InflaRx, a biopharmaceutical company, is its equity. The chart below shows the financial resources for commercializing its first approved drug and conducting further research. This is the story of the transition from an R&D company to a commercial one.
IFRX - Share of the company's book capitalization InflaRx N.V. within the market segment - Pharma immune
InflaRx is a biotech company developing antibodies to control inflammation. Its main asset is its scientific platform. The share of tangible assets will be low, reflecting its focus on R&D, where laboratories, rather than manufacturing facilities, are the primary facilities.
Market segment balance sheet capitalization - Pharma immune
InflaRx is a clinical-stage biotech company. Its value is created in labs, not factories. It's a "lightweight" model based on intellectual capital. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
InflaRx's assets represent capital invested in the development of drugs targeting the C5a protein in the complement system for the treatment of severe inflammatory diseases. The book value reflects the resources devoted to this innovative and complex therapeutic target.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - InflaRx N.V.
InflaRx is a German biotech company developing antibodies against the C5a component for the treatment of inflammatory diseases. Its market capitalization is a valuation of its lead drug and its potential for various conditions. The chart shows how investors are reacting to clinical trial data, which will shape the company's future.
Market to book capitalization ratio in a market segment - Pharma immune
InflaRx is a German biotech company developing drugs to control inflammation. Its value is determined by its scientific pipeline. The chart shows the premium investors are willing to pay for its innovative approach to treating inflammation compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
InflaRx is a biotech company developing drugs to control inflammation. The chart shows how the market views its scientific approach. The company's market capitalization is based on the potential of its lead drug candidate, which has already received approval for a specific indication, and on investors' confidence in its continued commercial success.
Debts of the company, segment and market as a whole
IFRX - Company debts InflaRx N.V.
InflaRx is a German biopharmaceutical company developing antibodies to control inflammation. While in clinical development, the company uses raised capital to fund its research in various therapeutic areas, as reflected in its financial strategy in this chart.
Market segment debts - Pharma immune
InflaRx is a biopharmaceutical company developing drugs to control inflammation by inhibiting the complement system. This is a promising area for the treatment of many diseases. The chart illustrates the financial norms for the biotech sector, where companies are raising significant capital to finance their expensive late-stage clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio InflaRx N.V.
InflaRx is a German biotech company developing drugs to control inflammatory processes in the body. Its research is aimed at developing therapies for severe diseases. This chart shows the debt-to-equity ratio, which provides insight into the company's financial vulnerability during its long clinical trials.
Market segment debt to market segment book capitalization - Pharma immune
Developing drugs to combat severe inflammatory reactions, like InflaRx, targets critical medical conditions. This chart shows how the biotech sector funds its innovations. It allows us to appreciate how this German company's financial model, with its unique approach to complement blocking, differs from other players.
Debt to book value of all companies in the market
InflaRx is a biopharmaceutical company fighting life-threatening inflammatory diseases. Developing critical care drugs is a high-risk and expensive endeavor. The chart shows how their debt strategy for funding clinical trials compares to the market.
P/E of the company, segment and market as a whole
P/E - InflaRx N.V.
This chart for InflaRx N.V., a biopharmaceutical company developing drugs to control inflammation, shows its market valuation. This metric reflects investors' faith in its scientific approach and the potential of its drugs to treat serious diseases where inflammation plays a key role.
P/E of the market segment - Pharma immune
This indicator represents the average valuation for the biotech sector in which InflaRx operates. It reflects the overall level of hope and expectation in the field of inflammatory disease treatments. The chart serves as a barometer of investor confidence in the future of immune system-controlling drugs.
P/E of the market as a whole
InflaRx is a German biotech company developing drugs to control inflammation. Its lead candidate targets severe skin diseases and COVID-19. This chart shows biotech sentiment. It helps understand how the market views InflaRx's scientific approach and the commercial prospects of its drugs in the competitive field of immunology and inflammatory diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company InflaRx N.V.
InflaRx is a German biotech company developing complement inhibitors for the treatment of severe inflammatory diseases. Its lead drug targets critically ill COVID-19 patients and other conditions. Its future depends on clinical success. This chart shows how investors view its scientific approach and potential in the critical care market.
%20P%2FE%20InflaRx%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-InflaRx-N.V.&v=1772513528627 "Chart of the company's future (projected) P/E InflaRx N.V.")
Future (projected) P/E of the market segment - Pharma immune
InflaRx is a German biotech company developing antibodies to control inflammatory processes in the immune system. The company's drugs are aimed at treating severe and life-threatening conditions. This chart reflects expectations for the biotech sector, helping to assess the market's view on this complex field of immunology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513528640 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
InflaRx is a German biotech company developing drugs targeting the complement system to treat severe inflammatory diseases. This graph of overall expectations shows the investor appetite for funding fundamental research. Market optimism and risk appetite are essential to support companies working on new biological targets and mechanisms of action.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513528650 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit InflaRx N.V.
InflaRx is a German biotech company developing antibodies to control inflammation. This chart shows the financial results of the company, whose lead drug has been approved for the treatment of COVID-19 patients. Profits now depend on sales of this drug and the success of expanding its use.
Profit of companies in the market segment - Pharma immune
Lee Enterprises, Incorporated is a media company that owns newspapers and digital publications in mid-market US markets. Its profitability, like DallasNews', is under pressure due to digital transformation. This chart reflects the struggle of traditional media for survival, where declining print revenues must be offset by growth in digital subscriptions and advertising.
Overall market profit
InflaRx is a German biotech company developing antibodies to control inflammatory processes. Its lead drug is aimed at treating severe and life-threatening conditions. The company's success depends on the results of clinical trials and regulatory approval, which could offer new treatment options for critically ill patients.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company InflaRx N.V.
InflaRx is a German biotech company developing antibodies to control inflammation. Its revenue forecast depends on the clinical and commercial success of its drugs targeting various inflammatory diseases. This chart reflects analyst expectations for the company's scientific platform and its developments.
%20profit%20of%20the%20company%20InflaRx%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-InflaRx-N.V.&v=1772513528813 "Graph of future (projected) profit of the company InflaRx N.V.")
Future (predicted) profit of companies in the market segment - Pharma immune
InflaRx is a German biopharmaceutical company developing drugs targeting the complement system, a component of the innate immune system. Its therapies are designed to treat severe inflammatory diseases. This chart shows profitability forecasts for the biotech sector. It reflects the potential and complexity of targeting fundamental mechanisms of the immune system.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513528851 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
InflaRx N.V. is a biotech company specializing in the development of drugs to control inflammation. Its success depends on the results of clinical trials. The corporate earnings forecast chart presented here is important because it forms the overall investment backdrop and influences the valuation of biotech companies when raising capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513528876 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - InflaRx N.V.
InflaRx is a German biotech company developing monoclonal antibodies targeting the complement system, which plays a key role in inflammation. Its lead drug is approved for the treatment of severe cases of COVID-19. The chart shows how investors view its current sales and the potential for its technology to be applied in other inflammatory diseases.
P/S market segment - Pharma immune
InflaRx N.V. is a clinical-stage biopharmaceutical company developing drugs to control inflammation by inhibiting the complement system. Its pipeline targets severe and life-threatening diseases. This chart shows the average market valuation for the sector, allowing one to assess how the market perceives the potential of InflaRx's research.
P/S of the market as a whole
InflaRx is a German biopharmaceutical company developing complement C5a inhibitors for the treatment of severe inflammatory diseases. The company already has an approved drug. This chart, showing average valuations, helps understand the market premium placed on the biotech company's revenue, which operates in the complex and promising field of immunology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company InflaRx N.V.
InflaRx is a German biotech company developing monoclonal antibodies to control inflammation. This chart shows how investors assess the future potential of its drugs. This assessment is based on expectations for their use in the treatment of severe and life-threatening inflammatory diseases, where there is an unmet need.
%20P%2FS%20InflaRx%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-InflaRx-N.V.&v=1772513528953 "The graph of the company's future (projected) P/S InflaRx N.V.")
Future (projected) P/S of the market segment - Pharma immune
InflaRx N.V. is a biopharmaceutical company developing monoclonal antibodies targeting the complement system for the treatment of severe inflammatory diseases. Its lead drug has demonstrated efficacy against COVID-19. The chart shows how investors estimate InflaRx's future sales, reflecting the potential of its anti-inflammatory platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513528959 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This chart reflects investor confidence in science's ability to control inflammation. InflaRx develops drugs that target a key component of the immune system—the complement system. The potential of their therapies to treat a range of severe inflammatory diseases supports long-term optimism about biotech innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513528970 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales InflaRx N.V.
InflaRx is a clinical-stage biopharmaceutical company developing antibodies to control inflammation. Its revenue at this stage comes from licensing fees and grants, not sales. This chart illustrates the financial impact of research pending approval and commercialization of its lead drug.
Sales of companies in the market segment - Pharma immune
InflaRx N.V. is a biopharmaceutical company developing complement C5a inhibitors to control inflammatory responses in severe and life-threatening conditions. This chart reflects the company's overall revenue in the immunology pharmaceutical sector. It demonstrates how a deep understanding of the immune system enables the development of targeted therapies to combat the most acute diseases.
Overall market sales
InflaRx is a German biopharmaceutical company developing drugs to control inflammatory processes by inhibiting the complement component C5a. Its therapy targets severe and life-threatening conditions. Success depends on clinical data. This overall economic activity schedule influences overall funding in the biotech sector, particularly in the field of critical care.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company InflaRx N.V.
InflaRx is a German biotech company developing complement C5a inhibitors for the treatment of severe inflammatory diseases. The company has one approved drug. The chart shows analyst revenue expectations, reflecting their sales forecasts for this drug and the potential of the company's other developments.
%20sales%20of%20the%20company%20InflaRx%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-InflaRx-N.V.&v=1772513529033 "Schedule of future (projected) sales of the company InflaRx N.V.")
Future (projected) sales of companies in the market segment - Pharma immune
InflaRx is a biopharmaceutical company developing complement inhibitors (specifically, C5a) for the treatment of severe inflammatory diseases. The company's success depends on clinical trials of its innovative drugs. This chart displays projected sales for the entire immunological pharmaceutical segment, demonstrating overall growth expectations for this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513529079 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
InflaRx is a German biopharmaceutical company developing complement inhibitors for the treatment of severe inflammatory diseases. The company has an approved drug and is continuing research. This overall economic activity schedule impacts healthcare system budgets, which determine the demand for innovative but expensive hospital medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513529097 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality InflaRx N.V.
InflaRx is a biotech company developing antibodies to control inflammation. This metric reflects its progress from development to commercialization. It demonstrates how successfully the company converts revenue from its first approved drug into net profit, covering marketing and further research costs.
Market segment marginality - Pharma immune
InflaRx is a biopharmaceutical company developing antibodies to control inflammation. Its profitability depends on the success of its drugs in treating serious diseases. This metric reflects its operational structure and the level of investment in its scientific platform compared to other immunology companies.
Market marginality as a whole
InflaRx is a German biopharmaceutical company developing antibodies to control inflammation. Their lead drug targets complement component C5a and has demonstrated efficacy against COVID-19. Their future depends on clinical success. This overall profitability curve doesn't directly impact them, but it is important for assessing the biotech sector as a whole.
Employees in the company, segment and market as a whole
Number of employees in the company InflaRx N.V.
InflaRx is a biotech company developing antibodies to control inflammation. Currently in the clinical stage, its core scientific team forms the core. This graph shows the dynamics of the team of scientists and clinicians, whose growth reflects progress in research and the advancement of its lead drug through clinical trials.
Share of the company's employees InflaRx N.V. within the market segment - Pharma immune
InflaRx is a German biopharmaceutical company developing antibodies against components of the complement system for the treatment of inflammatory diseases. This graph shows the concentration of leading immunologists in this complex field. The proportion of such specialists reflects its role as a leader in targeting this pathway.
Number of employees in the market segment - Pharma immune
InflaRx N.V. is a biopharmaceutical company developing complement inhibitors for the treatment of severe inflammatory diseases. This chart shows overall employment in the immunology research sector. It illustrates how InflaRx is working in the complex and promising field of immunology, seeking to control destructive inflammatory processes.
Number of employees in the market as a whole
InflaRx is a German biotech company developing antibodies to control inflammatory processes, particularly in severe infections and autoimmune diseases. This is a critical area of medicine. This employment chart also reflects the contribution of European biotech companies, which attract top scientific talent to develop innovative treatments for life-threatening conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company InflaRx N.V. (IFRX)
InflaRx N.V. is a biopharmaceutical company developing drugs to control inflammation by inhibiting the complement system. This chart demonstrates the market's high valuation of its scientific potential. High market capitalization per employee is the norm for biotech, as investors see value in the company's development pipeline and patents, not in operational metrics.
%20of%20the%20company%20InflaRx%20N.V.%20(IFRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-InflaRx-N.V.-IFRX&v=1772513529358 "Chart of market capitalization per employee (in thousands of dollars) of the company InflaRx N.V. (IFRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
InflaRx is a biopharmaceutical company specializing in the development of antibodies to control inflammation. Their key asset is their scientific platform. This chart shows the market premium for their innovative treatment approach. Their high market capitalization per employee indicates high expectations for their clinical programs and the potential to create a new class of drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513529436 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
InflaRx N.V. is a biopharmaceutical company developing drugs to control inflammation. The company has one approved drug. The employee's valuation will reflect both the current and future revenue from this drug and the value of the company's remaining research portfolio, which is typical for commercial biotech companies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513529466 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company InflaRx N.V. (IFRX)
InflaRx (IFRX) is a biotech company with an approved drug for the treatment of a rare inflammatory disease. They operate a hybrid model: they spend on R&D for new indications but are already generating revenue. This chart shows the net balance between commercial revenue and research expenses, per employee.
%20Chart%20InflaRx%20N.V.%20(IFRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-InflaRx-N.V.-IFRX&v=1772513529500 "Company Profit Per Employee (in thousands of dollars) Chart InflaRx N.V. (IFRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
InflaRx is a clinical-stage biotech developing antibodies to control inflammation. As with most biotechs in the R&D phase, this indicator is currently negative. The graph provides a benchmark for the future. Success will depend on whether their scientific team can create a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513529516 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
InflaRx (IFRX) is a biotech company developing drugs for inflammatory diseases by inhibiting the complement system. They have an approved drug. This chart shows their transition phase. It reflects the struggle between R&D and commercialization costs and the initial revenue generated by the sales team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513529560 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee InflaRx N.V. (IFRX)
This chart for InflaRx, a German biotech company developing drugs against inflammatory diseases, shows progress in commercializing its research. Growth in revenue per employee will depend on the success of its lead drug and the expansion of its use.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-InflaRx-N.V.-IFRX&v=1772513529588 "Sales chart per company employee InflaRx N.V. (IFRX)")
Sales per employee in the market segment - Pharma immune
InflaRx is a biopharmaceutical company specializing in the development of antibodies to control inflammatory processes. This metric reflects the average revenue per employee in the segment. It helps assess how productive their scientific team is in developing and commercializing their drugs compared to other biotech companies in the field of immunology.
Sales per employee for the market as a whole
InflaRx (IFRX) is a German clinical-stage biopharmaceutical company developing drugs to control inflammation. Currently, its staff consists primarily of scientists. This metric is pending for IFRX. It will only begin to grow if clinical trials are successful and either partner payments are received or marketing approval is obtained.
Short shares by company, segment and market as a whole
Shares shorted by company InflaRx N.V. (IFRX)
InflaRx is a German biotech company developing complement inhibitors for the treatment of inflammatory diseases. Its flagship drug has shown mixed results. This chart reflects investor bets that the company will fail to gain broad regulatory approval or that its drug will not be in demand by doctors in a competitive market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-InflaRx-N.V.-IFRX&v=1772513529770 "Short Shares Chart for the Company InflaRx N.V. (IFRX)")
Shares shorted by market segment - Pharma immune
InflaRx (IFRX) is a German biopharmaceutical company developing anti-inflammatory drugs targeting complement component C5a. This chart summarizes the bearish bets on the immunobiotech sector. It shows market skepticism regarding their specific therapeutic target or the commercial potential of their drugs.
Shares shorted by the overall market
InflaRx is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like IFRX in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator InflaRx N.V. (IFRX)
This chart demonstrates InflaRx's high sensitivity to clinical data. The company targets severe inflammatory diseases by blocking C5a. The approval of their COVID-19 drug sparked a surge in "overheating" (above 70). However, failures in other, larger indications (such as hidradenitis suppurativa) or weak sales of the approved drug quickly dampen investor enthusiasm (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-InflaRx-N.V.-IFRX&v=1772513529847 "RSI 14 indicator chart for the company's stock InflaRx N.V. (IFRX)")
RSI 14 Market Segment - Pharma immune
InflaRx (IFRX) is a German biotech company that "suppresses" the immune system. They are developing antibodies (anti-C5a) to treat severe inflammatory diseases (such as sepsis). The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It is vital to understand: is IFRX's growth due to their R&D or is the entire biotech sector "overheated"?
RSI 14 for the overall market
InflaRx (IFRX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IFRX (InflaRx N.V.)
InflaRx is a German biopharmaceutical company specializing in the development of antibodies (against C5a) for the treatment of severe inflammatory diseases. This chart shows the average target price from analysts, which is almost entirely dependent on their assessment of the company's R&D portfolio and the success of its clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IFRX-InflaRx-N.V.&v=1772513529967 "A chart showing analyst consensus forecasts for the expected stock price. IFRX (InflaRx N.V.)")
The difference between the consensus estimate and the actual stock price IFRX (InflaRx N.V.)
IFRX - InflaRx is a German biotech company developing antibodies to control the acute inflammatory response (C5a inhibition). This chart shows the difference between the current price and the analyst consensus estimate. It reflects their view on the clinical potential of this approach in treating severe diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IFRX-InflaRx-N.V.&v=1772513530003 "A chart showing the difference between the consensus forecast and the actual stock price. IFRX (InflaRx N.V.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
InflaRx (IFRX) is a German biotech company developing anti-inflammatory drugs (anti-C5a) aimed at treating severe infections and autoimmune diseases. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe in this targeted therapy.
Analysts' consensus forecast for the overall market share price
InflaRx is a German biotech company specializing in the development of drugs (antibodies) that block the complement system (part of the immune system) to treat severe inflammatory diseases. This chart shows the overall risk appetite. For InflaRx, a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index InflaRx N.V.
InflaRx (IFRX) is a German biotech company focused on inflammation. Their signature strategy is inhibiting the complement system (C5a), the first line of defense that goes haywire. This graph represents their R&D bet. It measures the commercial success of their first (approved) drug for a very rare disease (HS) and their hopes for other diseases.
AKIMA Market Segment Index - Pharma immune
InflaRx is a German biotech company specializing in the development of antibodies against C5a, a key protein in inflammatory processes (e.g., sepsis). This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how InflaRx's performance, with its highly targeted approach, compares to the sector average.
The AKIM Index for the overall market
InflaRx is a biotech company developing anti-inflammatory drugs targeting the complement system C5a (hidradenitis suppurativa). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story with commercial potential compares to overall economic trends.
